Navigation Links
Chiasma Reports Successful Oral Delivery Of A Peptide In Clinical Study
Date:6/13/2010

NEW YORK and JERUSALEM, June 14 /PRNewswire/ -- Chiasma, Inc., a privately held biopharma company, announced that it has successfully completed a Phase I clinical study evaluating the safety and pharmacokinetics (PK) of its proprietary product Octreolin, which contains the active ingredient octreotide actetate and is administered orally. Octreolin demonstrated a PK profile similar to that of subcutaneously injected octreotide acetate.  In addition, no serious adverse safety events were reported for Octreolin.

The Company also announced that it was advancing towards its goal of beginning a pivotal trial by the end of the year for Octreolin in acromegaly, a hormonal disorder that results from an excess of growth hormone (GH).

Chiasma has submitted an Orphan Drug application to the US FDA for acromegaly and will submit an application for Orphan Medicinal Product Designation to the European Agency for the Evaluation of Medicinal Products (EMEA) shortly. The Company intends to file an NDA using the 505(b)(2) regulatory pathway in the US and its EMEA equivalent, the Hybrid Application, in Europe.

Information on the Octreolin Trial

The Phase I trial was conducted in 12 healthy volunteers with a cross-over design in which subjects were each administered three single oral doses of Octreolin and a single subcutaneous injection of octreotide acetate as the reference drug (Sandostatin®). The primary objectives of the trial were to evaluate the safety, tolerability and PK of the three oral doses of Octreolin in comparison to the subcutaneous injection of octreotide acetate. Key findings included:


'/>"/>
SOURCE Chiasma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. QMed, Inc. Reports July Medicare SNP Enrollments
3. Phlo Affiliate Reports Expanded Coverage to Oregon Border
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Avitar Reports Third Quarter Financial Results for Fiscal 2007
8. Response Genetics Reports Second Quarter 2007 Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Transgenomic, Inc. Reports Second Quarter 2007 Results
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... , March 6, 2015   Senomyx , Inc. ... proprietary taste science technologies to discover, develop, and commercialize ... industries, announced today that John Poyhonen , the Company,s ... , Senior Vice President and Chief Financial Officer, will ... scheduled for Wednesday, March 11, at 2:00 p.m. Eastern ...
(Date:3/6/2015)... Die SARAH-Studie ... Assistance Publique - Hôpitaux de ... französische, gemeinschaftliche, randomisierte Kontrollstudie für die mehr ... werden Patienten mit fortgeschrittenem hepatozellulärem Karzinom (HCC), ... behandelt wurden. Die Ergebnisse werden für Ende ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 LifeCell Dx ... be able to get an Advanced Semen Analysis before ... blaming and guessing are all risk factors for struggling ... woman is the source of the infertility. Infertility is ... Dx has the simplest, least complicated and inexpensive ...
(Date:3/5/2015)... Park, NC (PRWEB) March 05, 2015 ... announced that Pierre Noel, M.D., Professor of Medicine, ... to the Company’s Board of Directors. ... “We are extremely fortunate to have Dr. Noel, ... country’s leading healthcare organization, join Entegrion’s Board. His ...
Breaking Biology Technology:SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE THE 27TH ANNUAL ROTH CONFERENCE 2Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 2Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 3Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 4Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 5Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 6LifeCell Dx Offers New Option to Veterans with Infertility 2LifeCell Dx Offers New Option to Veterans with Infertility 3Entegrion Announces Appointment of Pierre Noel, MD, to Its Board of Directors 2
... July 27, 2011 Once routinely discarded during the ... and potentially life-saving stem cells that can be collected ... proven uses and vast medical potential, published data shows ... "minimally informed" about cord blood banking. In ...
... July 27, 2011 Peloton Therapeutics, Inc., an early-stage ... completion of an $18 million Series A financing.  Led ... and Peter O,Donnell, Jr., the Series A funds supplement ... Prevention and Research Institute of Texas (CPRIT). ...
... LLC, a Chicago-based healthcare private equity firm, today ... Strata Pathology Services, Inc., a leading independent anatomic ... in Lexington, Massachusetts, Strata offers anatomic pathology services ... and gynecology segments. Since 1984, the company has ...
Cached Biology Technology:Parent's Guide to Cord Blood Foundation Launches Nation's First Searchable Map of U.S. Sites for Donating Umbilical Cord Blood 2Parent's Guide to Cord Blood Foundation Launches Nation's First Searchable Map of U.S. Sites for Donating Umbilical Cord Blood 3Peloton Therapeutics Completes $18 Million Series A Financing 2Peloton Therapeutics Completes $18 Million Series A Financing 3Linden Enters Anatomic Pathology Sector Through Investment in Strata Pathology Services, Inc. 2
(Date:2/10/2015)... Feb. 10, 2015  Alere Inc. (NYSE: ALR), ... financial results for the quarter ended December 31, ... and President of Alere said, "We made substantial ... as the global leader in rapid diagnostics and ... Alere Health divestiture in early January enabled us ...
(Date:2/5/2015)... 2015   Epic Sciences , a precision diagnostics company ... Murali Prahalad , Ph.D., president and CEO, is scheduled ... (PMWC) 2015: Silicon Valley, which is taking place at the ... on January 26-28, 2015. Dr. Prahalad ... Biomarkers." Last year, Epic Sciences was a finalist in the ...
(Date:2/5/2015)... , Jan. 28, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... upcoming RedChip Global Online CEO Conference on January 29 ... Gino Pereira , CEO of NXT-ID will present ... product, the Wocket smart wallet and its full suite ...
Breaking Biology News(10 mins):Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35Alere Inc. Announces Fourth Quarter 2014 Results 36
... The Institute of Medicine today presented the 2013 Gustav ... efforts to control tobacco use have helped save millions ... Schroeder,s leadership in general medicine as well as his ... great privilege to present this award to a dedicated ...
... October 21, 2013 Attention-deficit/hyperactivity disorder, or ADHD, is ... know what causes it, but genetics play a clear ... premature birth, low birth weight, a mother,s use of ... toxins like lead. ADHD is characterized by ...
... Subra Suresh has been elected a member of the ... university president to be elected to all three national ... highest professional distinctions accorded to engineers, scientists and medical ... made outstanding contributions to their fields. As one ...
Cached Biology News:Leader of smoking cessation and tobacco prevention efforts receives Institute of Medicine's 2013 Lienhard Award 2Leader of smoking cessation and tobacco prevention efforts receives Institute of Medicine's 2013 Lienhard Award 3Leader of smoking cessation and tobacco prevention efforts receives Institute of Medicine's 2013 Lienhard Award 4Do sunny climates reduce ADHD? 2Carnegie Mellon President Subra Suresh elected to Institute of Medicine 2
... He system uses a burst of ... nucleic acid-coated gold or tungsten microparticles ... tissues, or organelles without dependence or ... system includes helium pressure regulator, solenoid, ...
... Detection Kit contains a green fluorescent-labeled inhibitor, ... of valylalanylaspartic acid (VAD) fluoromethyl ketone (FMK), ... When added to a population of cells, ... and covalently binds to a reactive cysteine ...
... arrays have been developed for affinity ... A variety of ProteinChip chemical surfaces ... to their unique biochemical properties. Each ... side-by-side sample comparison, and the chips ...
Thermal printer paper is used with the thermal printer for the VersaFluor fluorometry systems. Supplied as 10 rolls....
Biology Products: